摘要
目的探究与分析米力农注射液对老年肺心病心衰患者心功能及血清N末端B型利钠肽原(NT-proBNP)、肌钙蛋白Ⅰ(cTnⅠ)及超敏C反应蛋白(hs-CRP)的影响。方法选取自2017年4月~2020年4月收治的老年慢性肺源性心脏病心力衰竭患者90例,采取随机数字表法分为对照组与观察组,每组各45例,两组在行常规治疗的基础上,对照组加用多巴酚丁胺治疗,观察组加用米力农注射液治疗,对比两组治疗前后临床疗效、心肺功能相关指标、血清NT-proBNP、cTnⅠ及hs-CRP及不良反应。结果观察组的临床总有效率明显高于对照组,差异具有统计学意义(P<0.05)。观察组治疗后与对照组治疗后相比PaCO_2较低、PaO_2较高、PAP较低、FEV_1/FVC较高、HR较低,血清NT-proBNP、cTnⅠ及hs-CRP均较低,差异具有统计学意义(P <0.05)。两组不良反应发生率差异无统计学意义(P> 0.05)。结论米力农注射液治疗老年慢性肺源性心脏病心力衰竭患者的临床效果显著,可显著改善心肺功能相关指标,无明显不良反应,安全性较高。
Objective To explore and analyze the curative effect of Milrinone injection in the treatment of heart failure with chronic cor pulmonale in the elderly and its influence on cardiac function indicators.Methods 90 cases of elderly patients with chronic cor pulmonale heart from April 2017 to April 2020 were selected.They were divided into control group and observation group with random number table method,45 cases in each group.On the basis of conventional treatment,control group treated with dobutamine,observation group added Milrinone injection.Clinical curative effect,the related parameters of cardiopulmonary function and adverse reactions were compared before and after treatment.Results The total clinical effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Compared with the control group after treatment,the observation group has lower PaCO2,higher PaO2,lower PAP,higher FEV1/FVC,lower HR,and lower serum NT-proBNP,cTnI and hs-CRP,and the difference were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Milrinone injection has a significant clinical effect in the treatment of elderly patients with chronic pulmonary heart disease and heart failure.It can significantly improve the related indices of cardiopulmonary function,with no obvious adverse reactions and high safety.
作者
于文华
YU Wen-hua(Department of Cardiology,Jinghai District Hospital,Tianjin 301600,China)
出处
《中国处方药》
2020年第12期82-84,共3页
Journal of China Prescription Drug
关键词
米力农注射液
老年慢性肺源性心脏病
心力衰竭
疗效
安全性
Milrinone injection
Chronic pulmonary heart disease in the elderly
Heart failure
Curative effect
Security